STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
- Conditions
- Myocardial Infarction
- Interventions
- Registration Number
- NCT00623623
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community hospital emergency room without a PCI facility. Following randomisation a strategy of early tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours with timely coronary intervention as appropriate (or by rescue coronary intervention if required) in Group A will be compared to primary PCI performed according to local standards in Group B.
The study is exploratory in nature and will examine this medical question. The efficacy and safety endpoints as well as mixed (efficacy and safety) composite endpoints up to or before 30 days following randomisation will be evaluated.
All clinical endpoints of main interest will be assessed as single or composite endpoints for evaluation of the trial objective. All statistical tests are of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1899
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Tenecteplase catheterisation Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention Tenecteplase enoxaparin Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention Tenecteplase clopidogrel Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention primary PCI primary PCI Standard primary PCI Tenecteplase tenecteplase Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention
- Primary Outcome Measures
Name Time Method Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. 30 days The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS).
- Secondary Outcome Measures
Name Time Method Number of Patients With All Cause Mortality 30 days This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported.
Number of Patients With Cardiogenic Shock 30 days This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported.
Number of Patients With Recurrent Myocardial Infarction (Reinfarction) 30 days This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported
Number of Patients With Rehospitalisation for Cardiac Reasons 30 days This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported
Number of Patients With Rehospitalisation for Non-cardiac Reasons 30 days This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported
Number of Patients With Cardiac Mortality 30 days This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported.
Number of Patients With Congestive Heart Failure (CHF) 30 days This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported.
Number of Patients With Serious Repeat Target Vessel Revascularization 30 days This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported
Number of Patients With All Cause Death and Shock 30 days This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported
Number of Patients With All Cause Death and Shock and CHF 30 days This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported.
Number of Patients With All Cause Death and Shock and Reinfarction 30 days This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported
Number of Patients With Total Fatal Stroke 30 days This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported
Number of Patients With Total Disabling Stroke 30 days This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported
Number of Patients With Total Non-disabling Stroke 30 days This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported
Number of Patients With Intracranial Haemorrhage 30 days This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported
Number of Patients With Ischaemic Stroke 30 days This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported
Number of Patients With Total Stroke (All Types) 30 days This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported
Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions 30 days This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported
Number of Patients With Minor Non-intracranial Bleeds 30 days This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported
Number of Patients With Total Non-intracranial Bleeds 30 days This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported
Number of Patients With Serious Resuscitated Ventricular Fibrillation 30 days This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported
Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures 30 days This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported
Number of Patients With All Cause Death and Non-fatal Stroke 30 days This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported
Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke 30 days This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported
Trial Locations
- Locations (200)
1123.28.39001A Boehringer Ingelheim Investigational Site
🇮🇹Monza, Italy
1123.28.3329A Boehringer Ingelheim Investigational Site
🇫🇷Aubervilliers Cedex, France
1123.28.3329C Boehringer Ingelheim Investigational Site
🇫🇷Aubervilliers Cedex, France
1123.28.3339A Boehringer Ingelheim Investigational Site
🇫🇷Le Chesnay Cedex, France
1123.28.3326A Boehringer Ingelheim Investigational Site
🇫🇷Lille, France
1123.28.3318A Boehringer Ingelheim Investigational Site
🇫🇷Lyon cedex 3, France
1123.28.3328A Boehringer Ingelheim Investigational Site
🇫🇷Montfermeil, France
1123.28.3328C Boehringer Ingelheim Investigational Site
🇫🇷Montfermeil, France
1123.28.3331A Boehringer Ingelheim Investigational Site
🇫🇷Paris, France
1123.28.3313B Boehringer Ingelheim Investigational Site
🇫🇷Nantes, France
1123.28.3322A Boehringer Ingelheim Investigational Site
🇫🇷Nice cedex 1, France
1123.28.3322B Boehringer Ingelheim Investigational Site
🇫🇷Nice cedex 1, France
1123.28.3357A Boehringer Ingelheim Investigational Site
🇫🇷Pessac, France
1123.28.3338A Boehringer Ingelheim Investigational Site
🇫🇷Poissy, France
1123.28.3316A Boehringer Ingelheim Investigational Site
🇫🇷Pringy Cedex, France
1123.28.3352A Boehringer Ingelheim Investigational Site
🇫🇷Pringy Cedex, France
1123.28.3310A Boehringer Ingelheim Investigational Site
🇫🇷Rouen cedex, France
1123.28.3345A Boehringer Ingelheim Investigational Site
🇫🇷Rouen, France
1123.28.3373A Boehringer Ingelheim Investigational Site
🇫🇷Vienne Cedex 9, France
1123.28.44110 Boehringer Ingelheim Investigational Site
🇬🇧Leicester, United Kingdom
1123.28.44100 Boehringer Ingelheim Investigational Site
🇬🇧Nottingham, United Kingdom
1123.28.3319C Boehringer Ingelheim Investigational Site
🇫🇷Bordeaux Cedex, France
1123.28.13004 Boehringer Ingelheim Investigational Site
🇨🇱Santiago, Chile
1123.28.3315A Boehringer Ingelheim Investigational Site
🇫🇷Besançon cedex, France
1123.28.43002 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1123.28.43009 Boehringer Ingelheim Investigational Site
🇦🇹Salzburg, Austria
1123.28.43010 Boehringer Ingelheim Investigational Site
🇦🇹Salzburg, Austria
1123.28.3376A Boehringer Ingelheim Investigational Site
🇫🇷Ambérieu en Bugey, France
1123.28.49002 Boehringer Ingelheim Investigational Site
🇩🇪Berlin, Germany
1123.28.49006 Boehringer Ingelheim Investigational Site
🇩🇪Berlin, Germany
1123.28.55001 Boehringer Ingelheim Investigational Site
🇧🇷Recife, Brazil
1123.28.11002 Boehringer Ingelheim Investigational Site
🇨🇦Newmarket, Ontario, Canada
1123.28.3329B Boehringer Ingelheim Investigational Site
🇫🇷Aubervilliers Cedex, France
1123.28.3346A Boehringer Ingelheim Investigational Site
🇫🇷Châteauroux cedex, France
1123.28.3336A Boehringer Ingelheim Investigational Site
🇫🇷Le Port-Marly, France
1123.28.3353A Boehringer Ingelheim Investigational Site
🇫🇷Grenoble, France
1123.28.3319A Boehringer Ingelheim Investigational Site
🇫🇷Bordeaux Cedex, France
1123.28.3307A Boehringer Ingelheim Investigational Site
🇫🇷Le Chesnay, France
1123.28.55018 Boehringer Ingelheim Investigational Site
🇧🇷Rio de Janeiro, Brazil
1123.28.3351B Boehringer Ingelheim Investigational Site
🇫🇷Besancon, France
1123.28.13005 Boehringer Ingelheim Investigational Site
🇨🇱Santiago, Chile
1123.28.3347B Boehringer Ingelheim Investigational Site
🇫🇷Bourges, France
1123.28.3317A Boehringer Ingelheim Investigational Site
🇫🇷La Tronche, France
1123.28.3387A Boehringer Ingelheim Investigational Site
🇫🇷Fort De France Cedex, France
1123.28.3353B Boehringer Ingelheim Investigational Site
🇫🇷Grenoble, France
1123.28.3388A Boehringer Ingelheim Investigational Site
🇫🇷Fort De France Cedex, France
1123.28.3347C Boehringer Ingelheim Investigational Site
🇫🇷Bourges, France
1123.28.3337A Boehringer Ingelheim Investigational Site
🇫🇷Evecquemont, France
1123.28.3339B Boehringer Ingelheim Investigational Site
🇫🇷Le Chesnay Cedex, France
1123.28.3317B Boehringer Ingelheim Investigational Site
🇫🇷La Tronche, France
1123.28.3301A Boehringer Ingelheim Investigational Site
🇫🇷Lille Cedex, France
1123.28.3325A Boehringer Ingelheim Investigational Site
🇫🇷Lille cedex, France
1123.28.3369B Boehringer Ingelheim Investigational Site
🇫🇷Lyon cedex 4, France
1123.28.3325B Boehringer Ingelheim Investigational Site
🇫🇷Lille cedex, France
1123.28.3308B Boehringer Ingelheim Investigational Site
🇫🇷Melun cedex, France
1123.28.3328B Boehringer Ingelheim Investigational Site
🇫🇷Montfermeil, France
1123.28.3356A Boehringer Ingelheim Investigational Site
🇫🇷Lyon cedex 7, France
1123.28.3318B Boehringer Ingelheim Investigational Site
🇫🇷Lyon cedex 3, France
1123.28.30003 Boehringer Ingelheim Investigational Site
🇬🇷Chalikida, Greece
1123.28.39201 Boehringer Ingelheim Investigational Site
🇮🇹Ferrara, Italy
1123.28.39200A Boehringer Ingelheim Investigational Site
🇮🇹Lagosanto (FE), Italy
1123.28.39082 Boehringer Ingelheim Investigational Site
🇮🇹Pescia (Pistoia), Italy
1123.28.3356B Boehringer Ingelheim Investigational Site
🇫🇷Lyon cedex 7, France
1123.28.3308A Boehringer Ingelheim Investigational Site
🇫🇷Melun cedex, France
1123.28.49026 Boehringer Ingelheim Investigational Site
🇩🇪Sömmerda, Germany
1123.28.3340A Boehringer Ingelheim Investigational Site
🇫🇷Melun, France
1123.28.3349B Boehringer Ingelheim Investigational Site
🇫🇷Nantes Cedex 1, France
1123.28.3379A Boehringer Ingelheim Investigational Site
🇫🇷Montelimar Cedex, France
1123.28.3369A Boehringer Ingelheim Investigational Site
🇫🇷Lyon cedex 4, France
1123.28.3349A Boehringer Ingelheim Investigational Site
🇫🇷Nantes Cedex 1, France
1123.28.30002 Boehringer Ingelheim Investigational Site
🇬🇷Leivadia, Greece
1123.28.30007 Boehringer Ingelheim Investigational Site
🇬🇷Thessaloniki, Greece
1123.28.30010 Boehringer Ingelheim Investigational Site
🇬🇷Thessaloniki, Greece
1123.28.30005 Boehringer Ingelheim Investigational Site
🇬🇷Thiva, Greece
1123.28.39008A Boehringer Ingelheim Investigational Site
🇮🇹Pistoia, Italy
1123.28.3378A Boehringer Ingelheim Investigational Site
🇫🇷Romans sur Isère, France
1123.28.3345B Boehringer Ingelheim Investigational Site
🇫🇷Rouen, France
1123.28.49052 Boehringer Ingelheim Investigational Site
🇩🇪Frankenthal, Germany
1123.28.77008 Boehringer Ingelheim Investigational Site
🇷🇺Murmansk, Russian Federation
1123.28.3344A Boehringer Ingelheim Investigational Site
🇫🇷Rouen Cedex, France
1123.28.3345C Boehringer Ingelheim Investigational Site
🇫🇷Rouen, France
1123.28.3384A Boehringer Ingelheim Investigational Site
🇫🇷Valence Cedex 9, France
1123.28.3377A Boehringer Ingelheim Investigational Site
🇫🇷Valence Cedex 9, France
1123.28.49008 Boehringer Ingelheim Investigational Site
🇩🇪Dortmund, Germany
1123.28.30011 Boehringer Ingelheim Investigational Site
🇬🇷Katerini, Greece
1123.28.47005 Boehringer Ingelheim Investigational Site
🇳🇴Hamar, Norway
1123.28.30009 Boehringer Ingelheim Investigational Site
🇬🇷Veroia, Greece
1123.28.39002A Boehringer Ingelheim Investigational Site
🇮🇹Genova, Italy
1123.28.39022 Boehringer Ingelheim Investigational Site
🇮🇹Genova, Italy
1123.28.39004A Boehringer Ingelheim Investigational Site
🇮🇹Imperia, Italy
1123.28.49012 Boehringer Ingelheim Investigational Site
🇩🇪Duisburg, Germany
1123.28.47001 Boehringer Ingelheim Investigational Site
🇳🇴Oslo, Norway
1123.28.19001 Boehringer Ingelheim Investigational Site
🇵🇪Lima, Peru
1123.28.48001 Boehringer Ingelheim Investigational Site
🇵🇱Poznan, Poland
1123.28.39011 Boehringer Ingelheim Investigational Site
🇮🇹Monza, Italy
1123.28.39081 Boehringer Ingelheim Investigational Site
🇮🇹Pistoia, Italy
1123.28.39041 Boehringer Ingelheim Investigational Site
🇮🇹Sanremo (IM), Italy
1123.28.70006 Boehringer Ingelheim Investigational Site
🇷🇺St. Petersburg, Russian Federation
1123.28.77001 Boehringer Ingelheim Investigational Site
🇷🇺Ekaterinburg, Russian Federation
1123.28.70005 Boehringer Ingelheim Investigational Site
🇷🇺Chelyabinsk, Russian Federation
1123.28.48006 Boehringer Ingelheim Investigational Site
🇵🇱Gniezno, Poland
1123.28.48009 Boehringer Ingelheim Investigational Site
🇵🇱Grodzisk Wielopolski, Poland
1123.28.70009 Boehringer Ingelheim Investigational Site
🇷🇺Irkutsk, Russian Federation
1123.28.77009 Boehringer Ingelheim Investigational Site
🇷🇺Irkutsk, Russian Federation
1123.28.77003 Boehringer Ingelheim Investigational Site
🇷🇺Nizhny Novgorod, Russian Federation
1123.28.70007 Boehringer Ingelheim Investigational Site
🇷🇺St. Petersburg, Russian Federation
1123.28.34001 Boehringer Ingelheim Investigational Site
🇪🇸Almeria, Spain
1123.28.70001 Boehringer Ingelheim Investigational Site
🇷🇺Ekaterinburg, Russian Federation
1123.28.77002 Boehringer Ingelheim Investigational Site
🇷🇺Kemerovo, Russian Federation
1123.28.38109 Boehringer Ingelheim Investigational Site
🇷🇸Sabac, Serbia
1123.28.34004 Boehringer Ingelheim Investigational Site
🇪🇸Granada, Spain
1123.28.44600 Boehringer Ingelheim Investigational Site
🇬🇧Belfast, United Kingdom
1123.28.44610 Boehringer Ingelheim Investigational Site
🇬🇧Belfast, United Kingdom
1123.28.44210 Boehringer Ingelheim Investigational Site
🇬🇧Bristol, United Kingdom
1123.28.44220 Boehringer Ingelheim Investigational Site
🇬🇧Bristol, United Kingdom
1123.28.34002 Boehringer Ingelheim Investigational Site
🇪🇸Malaga, Spain
1123.28.34003 Boehringer Ingelheim Investigational Site
🇪🇸Huelva, Spain
1123.28.44630 Boehringer Ingelheim Investigational Site
🇬🇧Newry, United Kingdom
1123.28.44620 Boehringer Ingelheim Investigational Site
🇬🇧Dundonald, United Kingdom
1123.28.34007 Boehringer Ingelheim Investigational Site
🇪🇸Madrid, Spain
1123.28.34011 Boehringer Ingelheim Investigational Site
🇪🇸Salamanca, Spain
1123.28.43001 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1123.28.43003 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1123.28.43004 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1123.28.32060 Boehringer Ingelheim Investigational Site
🇧🇪Bornem, Belgium
1123.28.43008 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1123.28.43005 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1123.28.32040 Boehringer Ingelheim Investigational Site
🇧🇪Liège, Belgium
1123.28.32010 Boehringer Ingelheim Investigational Site
🇧🇪Bruxelles, Belgium
1123.28.55020 Boehringer Ingelheim Investigational Site
🇧🇷Brasilia, Brazil
1123.28.32070 Boehringer Ingelheim Investigational Site
🇧🇪Herentals, Belgium
1123.28.55010 Boehringer Ingelheim Investigational Site
🇧🇷Brasilia, Brazil
1123.28.55008 Boehringer Ingelheim Investigational Site
🇧🇷Cabo Frio, Brazil
1123.28.55007 Boehringer Ingelheim Investigational Site
🇧🇷Porto Alegre, Brazil
1123.28.55017 Boehringer Ingelheim Investigational Site
🇧🇷Campinas, Brazil
1123.28.55004 Boehringer Ingelheim Investigational Site
🇧🇷Sao Paulo, Brazil
1123.28.55028 Boehringer Ingelheim Investigational Site
🇧🇷Rio de Janeiro, Brazil
1123.28.55016 Boehringer Ingelheim Investigational Site
🇧🇷Sao Lourenço do Sul, Brazil
1123.28.55014 Boehringer Ingelheim Investigational Site
🇧🇷Sao Paulo, Brazil
1123.28.13001 Boehringer Ingelheim Investigational Site
🇨🇱Santiago, Chile
1123.28.11505 Boehringer Ingelheim Investigational Site
🇨🇦Edmonton, Alberta, Canada
1123.28.11006 Boehringer Ingelheim Investigational Site
🇨🇦Edmonton, Alberta, Canada
1123.28.13002 Boehringer Ingelheim Investigational Site
🇨🇱Santiago, Chile
1123.28.3351A Boehringer Ingelheim Investigational Site
🇫🇷Besancon, France
1123.28.3315B Boehringer Ingelheim Investigational Site
🇫🇷Besançon cedex, France
1123.28.3302A Boehringer Ingelheim Investigational Site
🇫🇷Bobigny, France
1123.28.3302B Boehringer Ingelheim Investigational Site
🇫🇷Bobigny, France
1123.28.3383A Boehringer Ingelheim Investigational Site
🇫🇷Bourg-en-Bresse, France
1123.28.3319B Boehringer Ingelheim Investigational Site
🇫🇷Bordeaux Cedex, France
1123.28.3374A Boehringer Ingelheim Investigational Site
🇫🇷Bourg en Bresse, France
1123.28.3385A Boehringer Ingelheim Investigational Site
🇫🇷Bourg en Bresse, France
1123.28.3347A Boehringer Ingelheim Investigational Site
🇫🇷Bourges, France
1123.28.3355A Boehringer Ingelheim Investigational Site
🇫🇷Bron, France
1123.28.3355B Boehringer Ingelheim Investigational Site
🇫🇷Bron, France
1123.28.3382A Boehringer Ingelheim Investigational Site
🇫🇷Caluire et Cuire, France
1123.28.3311A Boehringer Ingelheim Investigational Site
🇫🇷Châteauroux cedex, France
1123.28.3311B Boehringer Ingelheim Investigational Site
🇫🇷Châteauroux cedex, France
1123.28.3346B Boehringer Ingelheim Investigational Site
🇫🇷Châteauroux cedex, France
1123.28.3309A Boehringer Ingelheim Investigational Site
🇫🇷Dreux, France
1123.28.3303A Boehringer Ingelheim Investigational Site
🇫🇷Clichy Cedex, France
1123.28.3342A Boehringer Ingelheim Investigational Site
🇫🇷Dreux, France
1123.28.3371A Boehringer Ingelheim Investigational Site
🇫🇷Paris, France
1123.28.3318C Boehringer Ingelheim Investigational Site
🇫🇷Lyon cedex 3, France
1123.28.3301B Boehringer Ingelheim Investigational Site
🇫🇷Lille Cedex, France
1123.28.3340B Boehringer Ingelheim Investigational Site
🇫🇷Melun, France
1123.28.3313A Boehringer Ingelheim Investigational Site
🇫🇷Nantes, France
1123.28.3322C Boehringer Ingelheim Investigational Site
🇫🇷Nice cedex 1, France
1123.28.3366A Boehringer Ingelheim Investigational Site
🇫🇷Nice cedex 1, France
1123.28.3375A Boehringer Ingelheim Investigational Site
🇫🇷Oyonnax, France
1123.28.3334A Boehringer Ingelheim Investigational Site
🇫🇷Paris cedex 10, France
1123.28.3310B Boehringer Ingelheim Investigational Site
🇫🇷Rouen cedex, France
1123.28.3341A Boehringer Ingelheim Investigational Site
🇫🇷Quincy-sous-Senart, France
1123.28.30001 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1123.28.30012 Boehringer Ingelheim Investigational Site
🇬🇷Alexandroupolis, Greece
1123.28.30014 Boehringer Ingelheim Investigational Site
🇬🇷Kavala, Greece
1123.28.30006 Boehringer Ingelheim Investigational Site
🇬🇷Korinthos, Greece
1123.28.39083 Boehringer Ingelheim Investigational Site
🇮🇹Pescia (Pistoia), Italy
1123.28.19004 Boehringer Ingelheim Investigational Site
🇵🇪Lima, Peru
1123.28.47002 Boehringer Ingelheim Investigational Site
🇳🇴Oslo, Norway
1123.28.48002 Boehringer Ingelheim Investigational Site
🇵🇱Gniezno, Poland
1123.28.70003 Boehringer Ingelheim Investigational Site
🇷🇺Nizhnyi Novgorod, Russian Federation
1123.28.70008 Boehringer Ingelheim Investigational Site
🇷🇺Murmansk, Russian Federation
1123.28.77005 Boehringer Ingelheim Investigational Site
🇷🇺Chelyabinsk, Russian Federation
1123.28.77004 Boehringer Ingelheim Investigational Site
🇷🇺Tomsk, Russian Federation
1123.28.70002 Boehringer Ingelheim Investigational Site
🇷🇺Kemerovo, Russian Federation
1123.28.77006 Boehringer Ingelheim Investigational Site
🇷🇺St. Petersburg, Russian Federation
1123.28.38101 Boehringer Ingelheim Investigational Site
🇷🇸Belgrade, Serbia
1123.28.70004 Boehringer Ingelheim Investigational Site
🇷🇺Tomsk, Russian Federation
1123.28.38110 Boehringer Ingelheim Investigational Site
🇷🇸Vrsac, Serbia
1123.28.44200 Boehringer Ingelheim Investigational Site
🇬🇧Chippenham, United Kingdom
1123.28.38106 Boehringer Ingelheim Investigational Site
🇷🇸Nis, Serbia
1123.28.38107 Boehringer Ingelheim Investigational Site
🇷🇸Nis, Serbia
1123.28.38103 Boehringer Ingelheim Investigational Site
🇷🇸Belgrade, Serbia
1123.28.38108 Boehringer Ingelheim Investigational Site
🇷🇸Smederevo, Serbia
1123.28.38111 Boehringer Ingelheim Investigational Site
🇷🇸Zajecar, Serbia
1123.28.38105 Boehringer Ingelheim Investigational Site
🇷🇸Zemun, Serbia
1123.28.13003 Boehringer Ingelheim Investigational Site
🇨🇱Santiago, Chile
1123.28.13006 Boehringer Ingelheim Investigational Site
🇨🇱Santiago, Chile
1123.28.38104 Boehringer Ingelheim Investigational Site
🇷🇸Zemun, Serbia
1123.28.43007 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria